category,datetime,headline,id,image,related,source,summary,url
company,1769031286,Alvotech: Why FDA Delays Don't Break The Bull Case,138200440,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159194981/image_2159194981.jpg?io=getty-c-w1536,ABBV,SeekingAlpha,"Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.",https://finnhub.io/api/news?id=37cb85cba880bde7dbd1e2759d21fcf2c7efcf23e1ff29fe3d128d489296803e
company,1769009460,FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate,138197142,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,Eli Lilly wins FDA Breakthrough Therapy status for sofetabart mipitecan in certain patients with platinum-resistant ovarian cancer.,https://finnhub.io/api/news?id=103c45e18deac07844851b1ebdbd5acccd9e3427805dc8db902c8902f578bce8
company,1769007039,Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon,138198106,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242759989/image_2242759989.jpg?io=getty-c-w1536,ABBV,SeekingAlpha,"Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many benefits, broad upside. Click for this CRVS update.",https://finnhub.io/api/news?id=e0cb69eae9c335eddda1ee9277683030abe30f4247fc28d9b0dae6a71bd4b1f0
company,1769004120,"Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference",138196024,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,"SAN DIEGO, January 21, 2026--Biocom today announced a distinguished keynote session for its 2026 Global Partnering & Investor Conference, taking place February 24 to 26 at The Lodge at Torrey Pines in La Jolla, California.",https://finnhub.io/api/news?id=7ded13c7bffe9a1eb7f0ee157151db09457910563196ab72f67489c6c0cd22d7
company,1768997445,AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market,138195095,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,"AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug […]",https://finnhub.io/api/news?id=165f92390b70c184bd2bb564d0da2507b936b6be0ef8d05d1a252659a674e8f6
